TL;DR
This paper presents a robust methodology for patient-specific quality assurance (QA) of Varian RapidArc treatment plans, a novel arc-based radiotherapy technique. The authors demonstrate that their approach, using a 2D diode array and an ion chamber, achieves high agreement between calculated and measured doses, ensuring treatment accuracy and patient safety.
What Problem Does This Paper Address?
Varian's RapidArc technology offers faster and potentially more precise radiation delivery by using a single, continuous arc. However, this novel approach introduces complexities in treatment planning and delivery that necessitate rigorous patient-specific quality assurance (QA) to ensure accuracy. Traditional QA methods, often designed for static beam delivery, may not fully capture the nuances of arc-based treatments, such as rotational geometry and varying dose rates. The authors identified a need for a consistent, efficient, and reliable QA methodology specifically tailored for RapidArc to validate treatment plans before delivery to patients.
Methods
The researchers developed a multi-faceted QA approach:
- 2D Diode Array Measurements: They utilized the MapCHECK device, a 2D diode array, embedded in the MapPHAN 5 phantom at a depth of 5 cm water equivalent. This setup allowed for planar dose distribution measurements in both coronal and sagittal planes.
- Ion Chamber Measurements: For point dose verification, an Exradin A16 ion chamber was used within a cylindrical QUASAR phantom. Six specific locations within the phantom were chosen to represent both high-dose and low-dose regions.
- Independent MU Calculation: To verify the number of monitor units (MUs) calculated by the treatment planning system (Eclipse), they employed independent software, RadCalc.
- Phantom Modeling: Crucially, they meticulously modeled the treatment couch and rails within the treatment planning system for phantom calculations to accurately account for beam attenuation, a factor often simplified or ignored in standard IMRT QA.
- Agreement Metrics: The agreement between calculated and measured doses was assessed using two primary metrics:
- Distance-to-Agreement (DTA): Measures the spatial difference between points of equal dose.
- Gamma Index: A more comprehensive metric that considers both dose difference and spatial distance, providing a pass/fail criterion. They used a 3%/3 mm criterion with a 10% dose threshold (TH).
- RadCalc MU Verification Strategy: For MU calculations, they initially used the average surface-to-source distance (SSD) from Eclipse. When discrepancies with RadCalc exceeded 5%, they implemented a strategy of dividing the arc into nine partial arcs for more accurate MU estimation.
Datasets
The study evaluated eleven RapidArc patients, including:
- Four prostate patients
- One prostate cone down patient
- Two prostate bed patients
- One trachea patient
- Three GYN patients
The QA measurements were performed using these patient plans. No new benchmark datasets were introduced; rather, the study focused on validating existing patient treatment plans.
Key Insights and Ideas
- Importance of Heterogeneity Corrections: The study highlighted that including couch structures and performing heterogeneous calculations in the phantom significantly improved the agreement between measurements and calculations compared to homogeneous calculations. This underscores the need to accurately model the phantom environment for reliable QA.
- Gamma Index Superiority: While both DTA and gamma index showed good agreement, the gamma index approach consistently yielded slightly higher agreement percentages, suggesting it might be a more sensitive metric for RapidArc QA.
- Strategic MU Verification: The approach of dividing arcs into partial plans for RadCalc MU verification proved effective in reducing discrepancies when initial calculations showed significant differences, demonstrating a practical solution for improving MU accuracy.
- Consistency Across Sites and Anatomies: The methodology yielded good results across a variety of treatment sites and patient anatomies, suggesting its broad applicability.
Key Results
- MapCHECK/MapPHAN 5 Agreement:
- Average agreement for the DTA approach was 94.4%.
- Average agreement for the gamma index approach was 96.3%.
- QUASAR Phantom Agreement:
- In high-dose areas for prostate cases, the discrepancy between calculations and ion chamber measurements was within 4.5%.
- RadCalc MU Agreement:
- After implementing the partial arc plan strategy for cases with >5% discrepancy, the agreement between RadCalc and Eclipse MUs was reduced to within ~4%.
Limitations and Future Work
- Dose Threshold Investigation: The authors noted that a higher dose threshold (e.g., 20% instead of 10%) might be more appropriate for analysis and plan to investigate this further.
- QUASAR Phantom Usage: QUASAR phantom measurements were performed for only three patients, suggesting this aspect of the QA could be expanded.
- Plane Selection for MapCHECK: The authors plan to determine the most appropriate plane (coronal or sagittal) for MapCHECK measurements based on treatment site to optimize efficiency.
- Future Detector Development: They anticipate that future, more advanced detectors will further enhance the capabilities for RapidArc QA.
- Software Upgrades: The paper mentions that future software upgrades (e.g., allowing simultaneous optimization for multiple arcs) are expected to further reduce planning and QA time, making it comparable to routine IMRT QA.
- Body Contour Import: Future RadCalc software is expected to import body contours, which should improve SSD estimation and agreement with Eclipse calculations.
Summary updated